[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"carcinoma-merkel-cell\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:carcinoma-merkel-cell":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100053225","phase-1-a-study-of-pembrolizumab-in-japanese-pediatric-participants-with-solid-tumors-or-lymphomas-and-japanese-adult-participants-with-merkel-cell-carcinoma-mk-3475-g21keynote-g21-100053225",false,"NCT07302347","A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21\u002FKEYNOTE-G21)","A Phase I\u002FII Study of Pembrolizumab (MK-3475) in Japanese Pediatric Participants With Specific Solid Tumors or Lymphomas, or in Japanese Adult Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-G21)","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\nArm 1:\n\n* For participants with relapsed or refractory classical Hodgkin lymphoma (cHL) or primary mediastinal large B-cell lymphoma (PMBCL)\n\n  * Has a confirmed diagnosis of relapsed or refractory cHL or PMBCL after the most recent therapy\n  * Has radiographically measurable disease per Lugano classification\n* For participants with completely resected melanoma:\n\n  * Has surgically completely resected and histologically\u002Fpathologically confirmed diagnosis of Stage IIB, IIC, III or IV cutaneous melanoma\n  * Has not received any prior systemic therapy for their melanoma beyond surgical resection\n  * All suspicious lesions amenable to biopsy are confirmed negative for malignancy\n* For participants with locally advanced or metastatic melanoma:\n\n  * Has histologically confirmed diagnosis of locally advanced (unresectable Stage III) or metastatic (Stage IV) melanoma (including acral) not amenable to local therapy\n  * Has radiographically measurable lesion(s) as defined by RECIST 1.1\n* For participants with microsatellite instability-high (MSI-H)\u002Fmismatch repair deficiency (dMMR) solid tumors:\n\n  * Has histologically\u002Fcytologically documented, locally-advanced, or metastatic solid malignancy that is incurable and has either (a) failed prior standard therapy, (b) for which no standard therapy exists, or (c) standard therapy is not considered appropriate by the participant and treating physician\n  * Has a documented positive local MSI-H or dMMR test result\n  * Has radiographically measurable disease based on RECIST 1.1\n* For participants with tumor mutational burden-high (TMB-H) solid tumors:\n\n  * Has histologically\u002Fcytologically documented, locally-advanced, or metastatic solid malignancy that is incurable and has either (a) failed prior standard therapy, (b) for which no standard therapy exists, or (c) standard therapy is not considered appropriate by the participant and treating physician\n  * Has radiographically measurable disease based on RECIST 1.1\n* For participants with MCC:\n\n  * Has histologically confirmed diagnosis of locoregional MCC that has recurred following standard locoregional therapy with surgery and\u002For radiation therapy and is not amenable to local therapy or metastatic MCC (Stage IV)\n  * Has radiographically measurable disease based on RECIST 1.1\n\nArm 2:\n\n* For participants with MCC:\n\n  * Has been untreated for advanced or metastatic disease\n\nArm 1 \\& Arm 2:\n\n* Life expectancy of \\>3 months (Arm 1) or \\>6 months (Arm 2)\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has known additional malignancy that is progressing or has required active treatment\n* Has known active (central nervous system) CNS metastases and\u002For carcinomatous meningitis\n* Has active autoimmune disease that has required systemic treatment in past 2 years\n* Has history of (noninfectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease\n* Has active infection requiring systemic therapy\n* Has known history of human immunodeficiency virus (HIV) infection\n* Has known history of Hepatitis B infection or known active Hepatitis C virus\n* Has undergone solid organ transplant at any time, or prior allogeneic hematopoietic stem cell transplantation within the last 5 years\n* Has not adequately recovered from major surgery or has ongoing surgical complications","ALL","6 Months",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE1","PHASE2","Researchers are looking for new ways to treat people with solid tumors, lymphomas (blood cancers), and a certain type of skin cancer. The goals of this study are to learn:\n\n* About the safety of pembrolizumab (the study medicine) and if people tolerate it\n* What happens to different doses of pembrolizumab in a person's body over time\n* How the cancer responds (gets smaller or goes away) to treatment",[27,28,29],"Malignant Neoplasm","Carcinoma, Merkel Cell","Lymphoma","RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2026-06-23",{"date":38,"type":20},"2029-12-31",{"name":40,"class":41},"Merck Sharp & Dohme LLC","INDUSTRY",7,{"id":44,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":45,"targetDuration":4,"studyType":21,"phases":46,"briefSummary":25,"conditions":47,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":54,"locationsCount":42},"100616187",{"count":19,"type":20},[23,24],[27,28,29],"2026-06-10",{"date":50,"type":34},"2026-06-12",{"date":52,"type":20},"2026-06-30",{"date":38,"type":20},{"name":40,"class":41},{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":62,"sex":16,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":4,"studyType":67,"phases":4,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":89},"100245278","studies-of-dermatologic-diseases-biospecimen-acquisition-protocol-100245278","NCT02471352","Studies of Dermatologic Diseases Biospecimen Acquisition Protocol","Studies of Dermatologic Diseases-Biospecimen Acquisition Protocol","* INCLUSION CRITERIA:\n* Eligible participants must:\n\n  * Have a dermatologic condition, as determined by the PI or AIs, OR --be at risk for developing a dermatologic condition, as determined by the PI or AIs, OR\n  * be a family member of a person with a dermatologic condition OR\n  * be a healthy volunteer, as defined as a person with no known significant health problems.\n  * Be willing to provide biospecimens for research and clinical studies, and for storage to be used for future research.\n  * Subjects of age greater than 0 years old (including only viable neonates) are eligible.\n\nEXCLUSION CRITERIA:\n\n* Presence of conditions that, in the judgment of the investigator, may put the subject at undue risk or make them unsuitable for participation in the study.\n* Inability to comply with the requirements of the protocol.",true,"1 Day","100 Years",{"count":66,"type":20},700,"OBSERVATIONAL","Background:\n\n\\- Skin disease can have many causes. It can have widespread consequences, and in rare cases can lead to death. Researchers want to determine the causes of various types of skin diseases and find a way to treat them.\n\nObjectives:\n\n\\- To determine the causes of various skin diseases and find ways to treat them.\n\nEligibility:\n\n* People ages 2 and older who have:\n\n  * A skin disease or at risk of developing a skin disease OR\n  * A family member of persons with a skin disease\n* Healthy volunteers ages 2 and older\n\nDesign:\n\n* Participants will be screened under a separate protocol.\n* Participants may take a survey about how their skin condition affects their quality of life.\n* Participants will have a medical history and a physical exam including a detailed skin exam. Pictures will be taken of their skin to document any skin disease.\n* Participants will have specimens collected. This may include:\n\n  * Several teaspoons of blood taken at each visit\n  * Stool samples\n  * Nail and body fluid (like saliva) samples\n  * Cheek swabs. The inside of the cheek will be scraped for about a minute in each direction to collect cells.\n  * Collection of skin samples with:\n\n    * A swab (like a Q-tip)\n    * Gently scraping skin to remove the outer layers of cells\n    * Applying and removing 1-inch pieces of tape\n* Participants may have up to 4 skin biopsies in 12 months, with 4 separate biopsies taken each time.\n\n  * An area of skin will be numbed with an injection.\n  * A piece of skin the size of a pencil eraser will be removed using a small instrument.\n  * A flat scar usually develops at the biopsy site.",[70,71,72,28],"Dermatologic Conditions","Healthy Volunteers","Normal Volunteers",[74,75,76,71,77,78],"Dermatologic Condition","Skin Disease","Biospecimen","Merkel Cell Carcinoma","Natural History","2026-05-28",{"date":81,"type":34},"2026-05-29",{"date":83,"type":34},"2015-06-19",{"date":85,"type":20},"2027-01-31",{"name":87,"class":88},"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","NIH",1]